Your browser doesn't support javascript.
loading
The Association of Metformin, Other Antidiabetic Medications, and Statins with the Prognosis of Hepatocellular Carcinoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study.
Tuunanen, Iida; Hautakoski, Ari; Huhtamäki, Heikki; Arffman, Martti; Sund, Reijo; Puistola, Ulla; Karihtala, Peeter; Jukkola, Arja; Urpilainen, Elina.
Afiliación
  • Tuunanen I; Department of Obstetrics and Gynecology, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, University of Oulu, 90220 Oulu, Finland.
  • Hautakoski A; Research Unit of Clinical Medicine, University of Oulu, 90220 Oulu, Finland.
  • Huhtamäki H; Medical Research Center, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, University of Oulu, 90220 Oulu, Finland.
  • Arffman M; Research Unit of Clinical Medicine, University of Oulu, 90220 Oulu, Finland.
  • Sund R; Medical Research Center, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, University of Oulu, 90220 Oulu, Finland.
  • Puistola U; Research Unit of Mathematical Sciences, Faculty of Science, University of Oulu, 90014 Oulu, Finland.
  • Karihtala P; Department of Public Health and Welfare, Finnish Institute for Health and Welfare, 00271 Helsinki, Finland.
  • Jukkola A; Institute of Clinical Medicine, University of Eastern Finland, 70029 Kuopio, Finland.
  • Urpilainen E; Department of Obstetrics and Gynecology, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, University of Oulu, 90220 Oulu, Finland.
Biomedicines ; 12(8)2024 Jul 24.
Article en En | MEDLINE | ID: mdl-39200117
ABSTRACT
This study aimed to explore whether the prediagnostic use of metformin and statins is associated with the prognosis of patients with hepatocellular carcinoma (HCC) and type 2 diabetes. We identified 1383 eligible individuals who had both type 2 diabetes and HCC diagnosed between 1998 and 2017 from several Finnish registers. Cox models were fitted for cause-specific and all-cause mortality in relation to the use of antidiabetic medications and statins prior to the HCC diagnosis. Prediagnostic metformin use was associated with decreased overall mortality (hazard ratio 0.84, 95% confidence interval 0.74-0.94) compared with nonuse in patients with type 2 diabetes. Similarly, slightly decreased HCC mortality and other-cause mortality were observed among metformin users. The results were inconclusive regarding metformin use and both overall and HCC mortality among patients with localized HCC. No discernible contrast between statin users and nonusers was found in overall mortality nor HCC mortality in either the whole cohort or patients with localized cancer.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2024 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2024 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Suiza